Skip to main content
SpringerLink
Log in

Present Role of Corticosteroids as Antiemetics

  • Conference paper
Book cover Supportive Care in Cancer Patients II

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 121))

Abstract

Many agents used as antiemetics induce severe side-effects. This paradox reduces the rate at which we can control cancer chemotherapy-induced nausea and vomiting. We need more effective agents and combinations thereof in this fight for a major goal in the quality of life of our patients. Indeed, total and not partial control of emesis is considered by most patients as the only clearly significant benefit from antiemetic treatment [1]. Should this goal not be achieved, many patients prefer antiemetic treatment giving minimal side-effects, such as with corticosteroids [2] or the recently developed serotonin (5HT3) receptor antagonists.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bennett JM, Byrne P et al. (1985) A randomized multicenter trial of cyclophosphamide, novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin and 5-fluorouracil ( CAF) in patients with metastatic breast cancer. Invest New Drugs 3: 179–185

    Article  PubMed  CAS  Google Scholar 

  2. Aapro MS, Plezia PM et al. (1984) Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 2: 466–471

    PubMed  CAS  Google Scholar 

  3. Borison HL, McCarthy LE (1983) Neuropharmacology of chemotherapy-induced emesis. Drugs 25 [Suppl 1]: 8–17

    Article  PubMed  CAS  Google Scholar 

  4. Akwari OE (1983) The gastrointestinal tract in chemotherapy-induced emesis. A final common pathway. Drugs 25 [Suppl I]: 18–34

    Article  PubMed  CAS  Google Scholar 

  5. Peroutka SJ, Synder SH (1982) Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet is 658

    Google Scholar 

  6. Bakowski MT (1984) Advances in anti-emetic therapy. Cancer Treat Rev 11: 237–256

    Article  PubMed  CAS  Google Scholar 

  7. Joss R, Galeazzi R et al. (1981) Nausea and Erbrechen bei der Chemotherapie maligner Tumoren. Schweiz Med Wochenschr 111: 1614–1622

    PubMed  CAS  Google Scholar 

  8. Pater JL, Willan AR (1984) Methodologic issues in trials of antiemetics. J Clin Oncol 2: 484–487

    PubMed  CAS  Google Scholar 

  9. Olver IN, Simon RM, Aisner J (1986) Antiemetic studies: a methodological discussion. Cancer Treat Rep 70: 555–563

    PubMed  CAS  Google Scholar 

  10. Morrow GR (1982) Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 68: 585–588

    PubMed  CAS  Google Scholar 

  11. Parliament MB, Danjoux CE et al. (1985) Is cancer treatment toxicity accurately reported? Int J Radiat Oncol Biol Phys 11: 603–608

    Article  PubMed  CAS  Google Scholar 

  12. Winokur SM, Baker JJ et al. (1981) Dexamethasone in the treatment of nausea and vomiting from cancer chemotherapy. J Med Assoc Ga 70: 263–264

    PubMed  CAS  Google Scholar 

  13. Baker JJ, Lockey JL et al. (1979) Nabilone as an antiemetic. N Engl J Med 301: 728

    Article  PubMed  CAS  Google Scholar 

  14. Rich NM, Abdulhayoglu G, Disaia RI (1980) Methylprednisolone as an antiemetic during cancer chemotherapy—a pilot study. Gynecol Oncol 9: 193–198

    Article  PubMed  CAS  Google Scholar 

  15. Lee BJ (1981) Methylprednisolone as an antiemetic. N Engl J Med 304: 486 (letter)

    Google Scholar 

  16. Aapro MS, Alberts DS (1981) High-dose dexamethasone for prevention of cisplatininduced vomiting. Cancer Chemother Pharmacol 7: 11–14

    Article  PubMed  CAS  Google Scholar 

  17. Morrow GR, Morrel C (1982) Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 307: 1476–1480

    Article  PubMed  CAS  Google Scholar 

  18. Breau JL, Israel L et al. (1983) Efficacité de la méthylprednisolone dans la prévention des vomissements dus aux chimiothérapies par sels de platine dans un essai randomisé. Presse Med 12: 2058

    PubMed  CAS  Google Scholar 

  19. Cassileth PA, Lusk EJ et al. (1983) Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med 43: 1347–1349

    Article  Google Scholar 

  20. Kolaric K, Roth A (1983) Methylprednisolone as an antiemetic in patients on cisplatinium chemotherapy. Results of a controlled randomized study. Tumori 69: 43–46

    PubMed  CAS  Google Scholar 

  21. Cognetti F, Pinnaro P et al. (1984) Randomized open cross-over trial between metoclopramide (MCP) and dexamethasone ( DXM) for the prevention of cisplatininduced nausea and vomiting. Eur J Cancer Clin Oncol 20: 183–187

    Article  PubMed  CAS  Google Scholar 

  22. Giaccone G, Donadio M et al. (1984) Comparison of the antiemetic effect of high-dose intravenous metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting. Tumori 70: 237–241

    PubMed  CAS  Google Scholar 

  23. Markman M, Sheider V et al. (1984) Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med 311: 549–552

    Article  PubMed  CAS  Google Scholar 

  24. Dana BW, Everts EC, Dickison D (1985) Dexamethasone vs placebo for cisplatininduced emesis. A randomized cross-over trial. Am J Clin Oncol 8: 426–428

    Google Scholar 

  25. D’Olimpio JT, Camacho F et al. (1985) Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy: a randomized double-blind controlled clinical trial. J Clin Oncol 3: 1133–1136

    PubMed  Google Scholar 

  26. Frustaci S, Grattoni E et al. (1986) Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone. Cancer Chemother Pharmacol 17: 75–79

    Article  PubMed  CAS  Google Scholar 

  27. Ibrahim EM, Al-Idrissi HY et al. (1986) Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy. Eur J Cancer Clin Oncol 39: 619–624

    Google Scholar 

  28. Shinkai T, Saijo N et al. (1986) Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial. Jpn J Clin Oncol 16: 279–287

    PubMed  CAS  Google Scholar 

  29. Niijima T, Isurugi K et al. (1986) Randomized cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy. Gan To Kagaku Ryoho 13: 2376–2382

    PubMed  CAS  Google Scholar 

  30. Chiara S, Scarsi P et al. (1984) Low dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting. Chemotherapia 3: 333–336

    CAS  Google Scholar 

  31. Campora E, Chiara S et al. (1985) The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial. Tumori 71: 459–462

    PubMed  CAS  Google Scholar 

  32. Giaccone G, Donadio M et al. (1984) Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting. Tumori 70: 237–241

    PubMed  CAS  Google Scholar 

  33. Osoba D, Erlichman C et al. (1986) Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy. Clin Invest Med 9: 225–231

    PubMed  CAS  Google Scholar 

  34. Metz CA, Freedman RS et al. (1987) Methylprednisolone in cis-platinum induced nausea and emesis: a placebo-controlled trial. Gynecol Oncol 27: 84–89

    Article  PubMed  CAS  Google Scholar 

  35. Martin Jimenez M, Diaz-Rubio E (1986) Atlas dosis de metilpredinisolona como tratamiento antiemético adyuvante de la metoclopramida en los vómitos inducidos por cisplatino. Resultados de un estudio controlado. Neoplasia 3: 61–63

    Google Scholar 

  36. Cunningham D, Evans C et al. (1987) Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. Br Med J 295: 250

    Article  CAS  Google Scholar 

  37. Roila F, Tonato M et al. (1987) Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. Eur J Cancer Clin Oncol 23: 615–617

    Article  PubMed  CAS  Google Scholar 

  38. Al-Idrissi HY, Ibrahim EM et al. (1988) Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine. Br J Cancer 57: 308–312

    Article  PubMed  CAS  Google Scholar 

  39. Basurto C, Roila F et al. (1988) A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents. Am J Clin Oncol 11: 594–596

    Article  PubMed  CAS  Google Scholar 

  40. Roila F, Basurto C et al. (1988) Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. Oncology 45: 346–349

    Article  PubMed  CAS  Google Scholar 

  41. Goldstein D, Levi JA, Woods RL et al. (1989) Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy. Oncology 46: 105–108

    Article  PubMed  CAS  Google Scholar 

  42. Pollera CF, Nardi M, Marolla Petal. (1989) Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trail with metoclopramide and placebo. Am J Clin Oncol 12: 524–529

    Article  PubMed  CAS  Google Scholar 

  43. Strum SB, Mc Dermed JE et al. (1985) High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy. J Clin Oncol 3: 245–251

    PubMed  CAS  Google Scholar 

  44. Poilera CF, Nardi M et al. (1987) A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin. Cancer Chemother Pharmacol 19: 335–338

    Google Scholar 

  45. Gathercole F, Connolly N, Birdsell J (1982) The use of dexamethasone (hexadrol) as an antiemetic in association with chemotherapy for neoplastic disease. Oncol Nurs Forum 9: 17–19

    PubMed  CAS  Google Scholar 

  46. Bruera E, Roca E et al. (1986) Improved control of chemotherapy induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep 67: 381–383

    Google Scholar 

  47. Colbert N, Izrael V et al. (1983) Adrenocorticotropic hormone in the prevention of cisplatin—induced nausea and vomiting. J Clin Oncol 1: 635–639

    PubMed  CAS  Google Scholar 

  48. Allan SG, Cornbleet MA et al. (1984) Dexamethasone and high-dose metoclopramide efficacy in controlling cisplatin-induced nausea and vomiting. Br Med J 289: 878–879

    Article  CAS  Google Scholar 

  49. Donovitz GS, O-Quinn AG et al. (1984) Antiemetic efficacy of high-dose corticosteroids and droperidol and metoclopramide. Gynecol Oncol 18: 320–325

    Article  PubMed  CAS  Google Scholar 

  50. Panza N, de Cesare M et al. (1984) Methylprednisolone and chlorpromazine alone or in combination for the control of cisplatin-induced emesis. Cancer Treat Rep 68: 1310–1311

    PubMed  CAS  Google Scholar 

  51. Benrubi GI, Norvell M et al. (1985) The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinum. Gynecol Oncol 21: 306–313

    Article  PubMed  CAS  Google Scholar 

  52. Ell C, Konig HJ et al. (1985) Antiemetic efficacy of moderately high-dose metoclopramide in patients receiving varying doses of cisplatin. Controlled comparison with a combination of methylprednisolone and metoclopramide. Oncology 42: 354–357

    Article  PubMed  CAS  Google Scholar 

  53. Becouarn Y, Nguyen B et al. (1986) Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial. Eur J Cancer Oncol 22: 1421–1424

    Article  CAS  Google Scholar 

  54. Fujii M, Kiura K et al. (1986) Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy. Gan To Kagaku Ryoho 13: 2562–2567

    PubMed  CAS  Google Scholar 

  55. Rhinehart SN, Dugan WM et al. (1986) The value of dexamethasone when added to combination drug therapy in the prevention of cisplatin-induced nausea and vomiting, evaluated by time-lapse video technology. Prog Clin Biol Res 216: 407–416

    PubMed  CAS  Google Scholar 

  56. Senn HJ, Kohler M et al. (1986) Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone. Dtsch Med Wochenschr 11: 129–135

    Article  Google Scholar 

  57. Shinkai T, Saijo N et al. (1986) Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial. Jpn J Clin Oncol 6: 279–287

    Google Scholar 

  58. Grunberg SM, Akerley WL et al. (1986) Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinuminduced emesis. Cancer Invest 4: 379–385

    Article  PubMed  CAS  Google Scholar 

  59. Roila F, Tonato M et al. (1987) Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5: 141–149

    PubMed  CAS  Google Scholar 

  60. Giaccone G, Bertetto O et al. (1988) High doses of methylprednisolone with or without alizapride in the prevention of cisplatin-induced emesis. A randomized, double-blind, crossover study. Oncology 45: 74–78

    Article  PubMed  CAS  Google Scholar 

  61. Martin Jiménez M, Diaz-Rubio E (1986) Actividad antiemetica de las altas dosis de metilprednisolona intravenosa en los vomitos inducicos por quimioterapia antineoplastica. Resultados de un estudio controlado. An Med Intern (Madr) 11: 525–528

    Google Scholar 

  62. Gez E, Brufman G, Kaufman B et al. (1989) Methylprednisolone and chlorpromazine in patients receiving cancer chemotherapy: a prospective non-randomized study. J Chemother 1: 140–143

    PubMed  CAS  Google Scholar 

  63. Basurto C, Roila F, Tonato M et al. (1989) Antiemetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. A randomized double-blind study of the Italian Oncology Group for Clinical Research. Am J Clin Oncol 12: 235–238

    Article  PubMed  CAS  Google Scholar 

  64. Carmichael J, Cantwell BMJ, Edwards CM, Rapeport WG, Harris AL (1988) The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin. Br Med J 297: 110–111

    Article  CAS  Google Scholar 

  65. Cunningham D, Turner A, Hawthorn J et al. (1989) Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Lancet is 1323

    Google Scholar 

  66. Roila F, Tonato M, Cognetti F et al. (1990) A double-blind multicentre randomized crossover study comparing the antiemetic efficacy and tolerability of ondansetron (OND) vs OND plus dexamethasone (DEX) in cisplatin (CDDP) treated cancer patients (PTS). Presented at the 2nd International Symposium on Supportive Care, St Gallen (this volume)

    Google Scholar 

  67. Ise T, Ohira A et al. (1982) Clinical evaluation of antiemetics for vomiting due to cancer chemotherapy in children. Gan To Kagaku Ryoho 9: 1108–1118

    PubMed  CAS  Google Scholar 

  68. Mehta P, Gross S et al. (1986) Methylprednisolone for chemotherapy-induced emesis: a double-blind randomized trial in children. J Pediatr 108: 774–776

    Article  PubMed  CAS  Google Scholar 

  69. Marshall G, Kerr S, Vowels M et al. (1989) Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benzotropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone. J Pediatr 115: 156–160

    CAS  Google Scholar 

  70. Matsumoto I, Aikawa T, Kanda T et al. (1989) Amelioration of cisplatin-induced vomiting and anorexia by methylprednisolone. Gan To Kagaku Ryoko 16: 833–838

    CAS  Google Scholar 

  71. Bloom BS (1989) Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med 149: 1019–1022

    Article  PubMed  CAS  Google Scholar 

  72. Levitt M, Sharma RN et al. (1979) Normal metyrapone response after 1 month of high-dose methylprednisolone in cancer patients: a phase I study. Cancer Treat Rep 63: 1327–1330

    PubMed  CAS  Google Scholar 

  73. Haid M (1981) Steroid antiemesis may be harmful. N Engl J Med 304: 1237

    PubMed  CAS  Google Scholar 

  74. Grunewald HW, Rosner F (1984) Dexamethasone as an antiemetic during cancer chemotherapy. Ann Intern Med 101: 398

    Google Scholar 

  75. Aapro MS, Alberts DS, Serokman R (1983) Lack of dexamethasone effect on the antitumor activity of cisplatin. Cancer Treat Rep 67: 1013–1017

    PubMed  CAS  Google Scholar 

  76. Baharav E, Harpaz D et al. (1986) Dexamethasone-induced perineal irritation. N Engl J Med 314: 515

    PubMed  CAS  Google Scholar 

  77. Allan SG, Leonard RCF (1986) Dexamethasone antiemesis and side-effects. Lancet is 1035

    Google Scholar 

  78. Thomas VL (1986) More on dexamethasone-induced perineal irritation. N Engl J Med 314: 1643

    Article  Google Scholar 

  79. Palmer MC, Colls BM (1987) Amelioration of cytotoxic-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam. Cancer Chemother Pharmacol 19: 331–334

    Article  PubMed  CAS  Google Scholar 

  80. Bluming AZ, Zeegen P (1986) Cataracts induced by intermittent decadron used as an antiemetic. J Clin Oncol 4: 221–223

    PubMed  CAS  Google Scholar 

  81. Demuynck B, Gramont A, de Gonzalez-Cavalli G et al. (1989) Randomized trial of sustained-release ACTH versus sustained-release ACTH and metoclopramide for the prevention of emesis induced by cyclophosphamide-adriamycin-5FU chemotherapy (in french). Semin Hôp Paris 65: 1742–1744

    Google Scholar 

  82. Stephen LC, Rine J et al. (1981) The role of prostaglandins in the excessive nausea and vomiting after intravascular cis-platinum therapy. Gynecol Oncol 12: 89–91

    Article  Google Scholar 

  83. Livera P, Trojano M, Simone IL et al. (1985) Acute changes in blood CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. J Neurol 231: 336–339

    Article  Google Scholar 

  84. Harris AL (1982) Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways. Lancet is 714

    Google Scholar 

  85. Drapkin RL, Sokl GH et al. (1982) The antiemetic effect and dose response of dexamethasone in patients receiving cis-platinum. Proc Am Soc Clin Oncol 1: 64 (abstr)

    Google Scholar 

  86. Chiara S, Campora E et al. (1987) Methylpredinisolonè for the control of CMFinduced emesis. Am J Clin Oncol 10: 264–267

    Article  PubMed  CAS  Google Scholar 

  87. Kessler JF, Alberts DS et al. (1986) An effective five-drug antiemetic combination for prevention of chemotherapy-related nausea and vomiting. Experience in eighty-four patients. Cancer Chemother Pharmacol 17: 282–286

    Article  Google Scholar 

  88. Kris MG, Richard JG et al. (1985) Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 55: 527–534

    Article  PubMed  CAS  Google Scholar 

  89. Kris MG, Gralla RJ, Tyson LB et al. (1989) Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7: 108–114

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division d’Onco-Hématologie, Hôpital Cantonal Universitaire, 24, Rue Micheli-du-Crest, 1211, Geneva 4, Switzerland

    M. S. Aapro

Authors
  1. M. S. Aapro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Klinik C, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland

    Hans-Jörg Senn  & Agnes Glaus  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Aapro, M.S. (1991). Present Role of Corticosteroids as Antiemetics. In: Senn, HJ., Glaus, A. (eds) Supportive Care in Cancer Patients II. Recent Results in Cancer Research, vol 121. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84138-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84138-5_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-84140-8

  • Online ISBN: 978-3-642-84138-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation